# SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference
Canonical URL: https://biopharmsignal.com/news/ICU/seastar-medical-to-present-at-upcoming-noble-capital-markets-emerging-growth-vir-7bccc30e
Ticker: ICU
Company: SeaStar Medical
Source: SeaStar Medical
Published: 2026-01-29 13:25 EST
## Summary

SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on...

## Article Body
SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, February 5th at 11:30 am Eastern Time.

Interested investors and guests of SeaStar Medical can register and view the live investor presentations here: Virtual Equity Conference Registration .

A replay of the SeaStar Medical presentation will be available on Monday, February 9 th after 11:30 am Eastern Time on the Company's website and can be accessed here . The replay will be available for up to 30 days following its posting.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. The QUELIMMUNE (SCD-PED) therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X .

Contact: SeaStar Investor Relations: IR@SeaStarMed.com
## Recent Company News
- 2026-07-14 12:34 EST — [SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)](https://biopharmsignal.com/news/ICU/seastar-medical-supports-advances-in-critical-care-of-pediatric-patients-with-ac-66530222) — Source: SeaStar Medical
- 2026-06-23 12:25 EST — [SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury](https://biopharmsignal.com/news/ICU/seastar-medical-announces-new-icd-10-pcs-codes-for-its-scd-therapy-for-acute-kid-ac132d55) — Source: SeaStar Medical
- 2026-06-22 12:45 EST — [SeaStar Medical to Present at Upcoming Investor Summit Conference](https://biopharmsignal.com/news/ICU/seastar-medical-to-present-at-upcoming-investor-summit-conference-599d1254) — Source: SeaStar Medical
- 2026-05-13 20:05 EST — [SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates](https://biopharmsignal.com/news/ICU/seastar-medical-reports-first-quarter-financial-results-and-provides-business-up-cbbf2b30) — Source: SeaStar Medical
- 2026-05-06 12:20 EST — [SeaStar Medical to Report First Quarter Financial Results on May 13, 2026](https://biopharmsignal.com/news/ICU/seastar-medical-to-report-first-quarter-financial-results-on-may-13-2026-b078aadd) — Source: SeaStar Medical
## Related News
- 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a)
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce)
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)